



SAFETY DATA SHEET

Revision date 17-Jun-2025

Version 3

Page 1 / 11

Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1. Product identifier

Product Name AMPICILLIN SODIUM-SULBACTAM SODIUM POWDER FOR INJECTION (Hospira, Inc.)
Product Code(s) PZ03457
Trade Name: Not applicable
Chemical Family: Mixture

1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use Pharmaceutical product used as antibiotic agent

1.3. Details of the supplier of the safety data sheet

Hospira, A Pfizer Company
275 North Field Drive
Lake Forest, Illinois 60045
1-800-879-3477

Pfizer Ireland Pharmaceuticals
OSG Building
Ringaskiddy, Co. Cork.
Ireland
+353 21 4378701

E-mail address pfizer-MSDS@pfizer.com

1.4. Emergency telephone number

Emergency Telephone Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887

Section 2: HAZARDS IDENTIFICATION

2.1. Classification of the substance or mixture

Respiratory sensitization Category 1
Skin sensitization Category 1

OSHA Classification

Hazards not otherwise classified (HNOC)
Not applicable

Hazards classified under paragraph (d)(1)(ii) of 1910.1200
Not applicable

2.2. Label elements



Signal word

Danger

SAFETY DATA SHEET

Product Name AMPICILLIN SODIUM-SULBACTAM SODIUM POWDER
FOR INJECTION (Hospira, Inc.)
Revision date 17-Jun-2025

Page 2 / 11
Version 3

Hazard statements

H334 - May cause allergy or asthma symptoms or breathing difficulties if inhaled
H317 - May cause an allergic skin reaction

**Precautionary Statements - EU (§28, P261 - Avoid breathing dust/fume/gas/mist/vapors/spray
1272/2008)**

P272 - Contaminated work clothing should not be allowed out of the workplace
P280 - Wear protective gloves/protective clothing/eye protection/face protection
P284 - In case of inadequate ventilation wear respiratory protection
P304 + P340 - IF INHALED: Remove person to fresh air and keep comfortable for breathing
P342 + P311 - If experiencing respiratory symptoms: Call a POISON CENTER or doctor/physician
P333 + P313 - If skin irritation or rash occurs: Get medical advice/attention
P362 + P364 - Take off contaminated clothing and wash it before reuse
P501 - Dispose of contents/container in accordance with local, regional, national, and international regulations as applicable
P302 + P352 - IF ON SKIN: Wash with plenty of soap and water

2.3. Other hazards

Other hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

PBT & vPvB

The product does not contain any substance(s) classified as PBT or vPvB.

Endocrine Disruptor Information

This product does not contain any known or suspected endocrine disruptors.

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Substances

Not applicable

3.2 Mixtures

Hazardous

Chemical name	Weight-%	REACH registration number	EC No (EU Index No)	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Ampicillin sodium (CAS #: 69-52-3)	66		200-708-1	Resp. Sens.1 (H334) Skin Sens.1 (H317)	Not classified	No data available	No data available
Sulbactam sodium (CAS #: 69388-84-7)	44		273-984-4	Not classified	Not classified	No data available	No data available

SAFETY DATA SHEET

Product Name AMPICILLIN SODIUM-SULBACTAM SODIUM POWDER
FOR INJECTION (Hospira, Inc.)
Revision date 17-Jun-2025

Page 3 / 11
Version 3

Full text of H- and EUH-phrases: see section 16

Acute Toxicity Estimate No information available

Chemical name	Oral LD50 mg/kg	Dermal LD50 mg/kg	Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
Ampicillin sodium 69-52-3	5314	No data available	No data available	No data available	No data available
Sulbactam sodium 69388-84-7	>4000	No data available	No data available	No data available	No data available

This product does not contain candidate substances of very high concern at a concentration >=0.1% (Regulation (EC) No. 1907/2006 (REACH), Article 59).

Additional information

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

Section 4: FIRST AID MEASURES

4.1. Description of first aid measures

Inhalation	Remove to fresh air. Seek immediate medical attention/advice.
Eye contact	Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician.
Skin contact	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
Ingestion	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

4.2. Most important symptoms and effects, both acute and delayed

Most important symptoms and effects	For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
--	--

4.3. Indication of any immediate medical attention and special treatment needed

Note to physicians	None.
---------------------------	-------

Section 5: FIRE-FIGHTING MEASURES

5.1. Extinguishing media

Suitable Extinguishing Media	Dry chemical, CO ₂ , alcohol-resistant foam or water spray.
-------------------------------------	--

5.2. Special hazards arising from the substance or mixture

Specific hazards arising from the chemical	Fine particles (such as dust and mists) may fuel fires/explosions.
---	--

Hazardous combustion products	Formation of toxic gases is possible during heating or fire.
--------------------------------------	--

Explosion data

SAFETY DATA SHEET

Product Name AMPICILLIN SODIUM-SULBACTAM SODIUM POWDER
FOR INJECTION (Hospira, Inc.)
Revision date 17-Jun-2025

Page 4 / 11
Version 3

Sensitivity to mechanical impact No information available.
Sensitivity to static discharge No information available.

5.3. Advice for firefighters

Special protective equipment and precautions for fire-fighters Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.

Section 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

For emergency responders Use personal protection recommended in Section 8.

6.2. Environmental precautions

Environmental precautions Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

6.3. Methods and material for containment and cleaning up

Methods for containment Prevent further leakage or spillage if safe to do so.

Methods for cleaning up Contain the source of the spill or leak. Collect spilled material by a method that controls dust generation. Avoid use of a filtered vacuum to clean spills of dry solids. Clean contaminated surface thoroughly.

Prevention of secondary hazards Clean contaminated objects and areas thoroughly observing environmental regulations.

6.4. Reference to other sections

Reference to other sections See section 8 for more information. See section 13 for more information.

Section 7: HANDLING AND STORAGE

7.1. Precautions for safe handling

Advice on safe handling Minimize dust generation and accumulation. Avoid breathing dust/fume/gas/mist/vapors/spray. Avoid contact with skin, eyes or clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.

7.2. Conditions for safe storage, including any incompatibilities

Storage Conditions Store as directed by product packaging.

7.3. Specific end use(s)

Specific use(s) Pharmaceutical drug product.

SAFETY DATA SHEET

Product Name AMPICILLIN SODIUM-SULBACTAM SODIUM POWDER
FOR INJECTION (Hospira, Inc.)
Revision date 17-Jun-2025

Page 5 / 11
Version 3

Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control parameters

Exposure Limits

Refer to available public information for specific member state Occupational Exposure Limits.

Sulbactam sodium

Pfizer OEL TWA-8 Hr: 3000 µg/m³, (as free acid)

Pfizer Occupational Exposure Band

(OEB) Statement:

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

8.2. Exposure controls

Engineering controls

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal protective equipment

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

Eye/face protection

Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).

Hand protection

Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).

Skin and body protection

Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).

Respiratory protection

Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.).

Thermal hazards

No information available.

Environmental exposure controls

No information available.

SAFETY DATA SHEET

Product Name AMPICILLIN SODIUM-SULBACTAM SODIUM POWDER
FOR INJECTION (Hospira, Inc.)
Revision date 17-Jun-2025

Page 6 / 11
Version 3

Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

Physical state	Powder
Color	Off-white
Odor	Odorless.
Odor threshold	No information available
Property	Values
Melting point / freezing point	No data available
Boiling point or initial boiling point and boiling range	No data available
Flammability (solid, gas)	No data available
Lower and upper explosion limit/flammability limit	
Lower explosion limit	No data available
Upper explosion limit	No data available
Flash point	No data available
Autoignition temperature	No data available
Decomposition temperature	
SADT (°C)	No data available
pH	8 - 10
pH (as aqueous solution)	No data available
Kinematic viscosity	No data available
Dynamic viscosity	No data available
Solubility	Soluble Water
Vapor pressure	No data available
Density and/or relative density	
Bulk density	No data available
Liquid Density	No data available
Vapor density	No data available
Particle characteristics	
Particle Size	No information available
Particle Size Distribution	No information available

9.2. Other information

Molecular formula	Mixture
Molecular weight	Mixture

9.2.1. Information with regard to physical hazard classes

No information available

9.2.2. Other safety characteristics

No information available

Section 10: STABILITY AND REACTIVITY

10.1. Reactivity

Reactivity No information available.

10.2. Chemical stability

Stability Stable under normal conditions.

Explosion data

Sensitivity to mechanical impact No information available.

Sensitivity to static discharge No information available.

10.3. Possibility of hazardous reactions

SAFETY DATA SHEET

Product Name AMPICILLIN SODIUM-SULBACTAM SODIUM POWDER
FOR INJECTION (Hospira, Inc.)
Revision date 17-Jun-2025

Page 7 / 11
Version 3

Possibility of hazardous reactions No information available.

Hazardous polymerization Will not occur.

10.4. Conditions to avoid

Conditions to avoid Fine particles (such as dust and mists) may fuel fires/explosions.

10.5. Incompatible materials

Incompatible materials As a precautionary measure, keep away from strong oxidizers.

10.6. Hazardous decomposition products

Hazardous decomposition products No data available.

Section 11: TOXICOLOGICAL INFORMATION

11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

General Information: The information included in this section describes the potential hazards of various forms of the active ingredient. The toxicities of the two materials can be expected to be similar.

Short term Accidental ingestion may cause effects similar to those seen in clinical use. Ampicillin is reported to induce environmental or occupational asthma. Individuals who are allergic to penicillin antibiotics could have allergic reaction, possibly severe (anaphylactic).

Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on liver. Adverse effects seen during clinical use are infrequent (<3%) and include diarrhea and skin rash. Pseudomembranous colitis has been reported following the use of Unasyn®.

Acute toxicity

Serious eye damage/eye irritation Based on available data, the classification criteria are not met.

Skin corrosion/irritation Based on available data, the classification criteria are not met.

Respiratory or skin sensitization Based on available data, the classification criteria are not met.

STOT - single exposure Based on available data, the classification criteria are not met.

STOT - repeated exposure Based on available data, the classification criteria are not met.

Reproductive toxicity Based on available data, the classification criteria are not met.

Germ cell mutagenicity Based on available data, the classification criteria are not met.

Carcinogenicity Based on available data, the classification criteria are not met.

Aspiration hazard Based on available data, the classification criteria are not met.

Acute Toxicity: (Species, Route, End Point, Dose)

Ampicillin sodium

Rat Oral LD50 > 5314 mg/kg

Mouse Oral LD50 > 5314 mg/kg

Rat SC LD50 > 5314 mg/kg

Mouse SC LD50 > 5314 mg/kg

Rat IP LD50 7400 mg/kg

Sulbactam sodium

Rat Oral LD50 > 4000 mg/kg

Mouse Oral LD50 > 10,000 mg/kg

Rat IV LD50 4582 mg/kg

Mouse IV LD50 3604 mg/kg

Ampicillin trihydrate

Rat Oral LD50 10,000 mg/kg

Mouse Oral LD50 15,200 mg/kg

Ampicillin

Rat Oral LD 50 10000 mg/kg

Rat Sub-tenon injection (eye) LD 50 4500 mg/kg

Mouse Oral LD 50 > 5000 mg/kg

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Ampicillin sodium	> 5314 mg/kg (Rat)	-	-

SAFETY DATA SHEET

Product Name AMPICILLIN SODIUM-SULBACTAM SODIUM POWDER
FOR INJECTION (Hospira, Inc.)
Revision date 17-Jun-2025

Page 8 / 11
Version 3

--	--	--	--

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Skin Irritation / Sensitization Hypersensitivity reactions can occur in individuals sensitive to penicillin, streptomycin, and/or other aminoglycosides. Mild irritation was seen in 3-day venous irritation studies in rabbits with sulbactam/ampicillin. Ampicillin is reported to induce environmental or occupational asthma.

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Sulbactam sodium

6 Month(s) Rat Subcutaneous 20 mg/kg/day NOAEL Liver
35 Day(s) Dog Oral 200 mg/kg/day LOAEL None identified
36 Day(s) Rat Oral 200 mg/kg/day LOAEL Liver

Ampicillin trihydrate

103 Week(s) Rat Oral 750 mg/kg/day LOEL Gastrointestinal System
103 Week(s) Mouse Oral 1500 mg/kg/day LOEL Gastrointestinal system

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Sulbactam sodium

Reproductive & Fertility Rat Subcutaneous 120 mg/kg/day NOAEL Negative
Prenatal & Postnatal Development Mouse Rat Intramuscular 800 mg/kg/day NOAEL Not Teratogenic

Ampicillin trihydrate

Fertility and Embryonic Development Rat Oral 2500 mg/kg/day LOEL Fetotoxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Sulbactam sodium

Bacterial Mutagenicity (Ames) *Salmonella* Negative
In Vitro Cytogenetics Human Lymphocytes Negative
In Vivo Cytogenetics Mouse Bone marrow Negative

Ampicillin trihydrate

Bacterial Mutagenicity (Ames) *Salmonella* Negative
Mammalian Cell Mutagenicity Mouse Lymphoma Negative
Sister Chromatid Exchange Chromosome Aberration Chinese Hamster Ovary (CHO) cells Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Ampicillin trihydrate

103 Week(s) Mouse Oral 3000 mg/kg/day NOEL Not carcinogenic
103 Week(s) Female Rat Oral 1500 mg/kg/day NOEL Not carcinogenic
103 Week(s) Male Rat Oral 750 mg/kg/day LOEL Malignant tumors, Adrenal gland, Blood

Carcinogenicity

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. See below

Ampicillin sodium

IARC Group 3

11.2. Information on other hazards

11.2.1. Endocrine disrupting properties

Endocrine disrupting properties Based on available data, the classification criteria are not met.

11.2.2. Other information

Other adverse effects

No information available.

SAFETY DATA SHEET

Product Name AMPICILLIN SODIUM-SULBACTAM SODIUM POWDER
FOR INJECTION (Hospira, Inc.)
Revision date 17-Jun-2025

Page 9 / 11
Version 3

Section 12: ECOLOGICAL INFORMATION

Environmental Overview: The environmental characteristics of this mixture have not been fully evaluated. Releases to the environment should be avoided.

12.1. Toxicity

12.2. Persistence and degradability

Persistence and degradability No information available.

12.3. Bioaccumulative potential

Bioaccumulation No information available.

12.4. Mobility in soil

Mobility in soil No information available.

12.5. Results of PBT and vPvB assessment

PBT and vPvB assessment Based on available data, the classification criteria are not met.

12.6. Endocrine disrupting properties

Endocrine disrupting properties Based on available data, the classification criteria are not met.

12.7. Other adverse effects

Other adverse effects No information available.

PMT or vPvM properties Based on available data, the classification criteria are not met.

Section 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods

Waste from residues/unused products

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

SAFETY DATA SHEET

Product Name AMPICILLIN SODIUM-SULBACTAM SODIUM POWDER
FOR INJECTION (Hospira, Inc.)
Revision date 17-Jun-2025

Page 10 / 11

Version 3

UN number: Not applicable
UN proper shipping name: Not applicable
Transport hazard class(es): Not applicable
Packing group: Not applicable
Environmental Hazard(s): Not applicable

Section 15: REGULATORY INFORMATION

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Ampicillin sodium	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
EINECS	200-708-1
Sulbactam sodium	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
EINECS	273-984-4

National regulations

Germany

Chemical Prohibition Ordinance (ChemVerbotsV)

TRGS 905 Not applicable

Switzerland

Ordinance on the Incentive Tax on Volatile Organic Compounds (OVOC) SR 814.018	Not applicable
Storage of Hazardous Material	Not applicable
WPO (GSchV) SR 814.201; WPA (GSchG) SR 814.20	Not applicable
Major Accidents Ordinance SR 814.012	Not applicable

European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work.

Authorizations and/or restrictions on use:

This product does not contain substances subject to authorization (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Persistent Organic Pollutants

Not applicable

Ozone-depleting substances (ODS) Regulation (EU) 2024/590

Not applicable.

SAFETY DATA SHEET

Product Name AMPICILLIN SODIUM-SULBACTAM SODIUM POWDER
FOR INJECTION (Hospira, Inc.)
Revision date 17-Jun-2025

Page 11 / 11
Version 3

Explosives Precursors Marketing and Use (2019/1148)
Not applicable

Legend:

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory
DSL/NDSL - Canadian Domestic Substances List/Non-Domestic Substances List
EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances
ENCS - Japan Existing and New Chemical Substances
IECSC - China Inventory of Existing Chemical Substances
KECL - Korean Existing Chemicals Inventory
PICCS - Philippines Inventory of Chemicals and Chemical Substances
AICS - Australian Inventory of Chemical Substances
NZIoC - New Zealand Inventory of Chemicals
TCSI - Taiwan Chemical Substance Inventory

15.2. Chemical safety assessment

Chemical Safety Report No information available

Section 16: OTHER INFORMATION

Key or legend to abbreviations and acronyms used in the safety data sheet

Full text of any hazard and/or precautionary statements referred to under Sections 2-15

H334 - May cause allergy or asthma symptoms or breathing difficulties if inhaled H317 - May cause an allergic skin reaction

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Reason for revision Updated Section 3 - Composition / Information on Ingredients. Updated Section 11 - Toxicology Information. Updated Section 12 - Ecological Information.

Revision date 17-Jun-2025

Prepared By Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.